Key Highlights
- Aethlon Medical (Nasdaq: AEMD) signed a definitive all-stock Merger agreement with North Immunology alongside an intended $180 million private financing.
- The combined entity will trade as North Immunology under the ticker NRTX, with a pro forma Equity valuation near $346.5 million.
- Existing North investors will hold 95.25% of the combined company; Aethlon Medical shareholders will hold 4.75% plus a Hemopurifier contingent value right.
- Capital raised is intended to fund lead candidate NOR-101 into Phase 1 studies in the first quarter of 2027.
Merger Creates North Immunology
Aethlon Medical (Nasdaq: AEMD) has entered into a definitive all-stock merger agreement with North Immunology, paired with an intended $180 million private financing. The combined company will operate under the North Immunology name and trade under the ticker NRTX, with a pro forma equity valuation of approximately $346.5 million.
Ownership Split and Runway
Under the terms of the deal, existing North Immunology investors will hold approximately 95.25% of the combined company, while Aethlon Medical (Nasdaq: AEMD) shareholders will retain 4.75%, alongside a contingent value right tied to Aethlon's existing Hemopurifier technology. The financing is intended to provide runway through the second half of 2028, funding lead bispecific antibody candidate NOR-101 into Phase 1 clinical studies scheduled to begin in the first quarter of 2027.
Deal Structure Reflects Reverse merger Dynamics
The transaction structure, with North Immunology investors retaining the substantial majority of combined equity, reflects a common reverse-merger pathway for private biotechs seeking public market access through a smaller listed company such as Aethlon Medical (Nasdaq: AEMD).
What will the combined company be named?
North Immunology, trading under the ticker NRTX.
How is ownership split in the merger?
North Immunology investors will hold approximately 95.25%, with Aethlon Medical shareholders holding 4.75% plus a Hemopurifier contingent value right.
What is NOR-101?
North Immunology's lead bispecific antibody candidate, expected to enter Phase 1 studies in the first quarter of 2027.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...